Log in

OTCMKTS:NBIONascent Biotech Stock Price, Forecast & News

-0.01 (-9.09 %)
(As of 05/25/2020 01:37 PM ET)
Today's Range
Now: $0.10
50-Day Range
MA: $0.16
52-Week Range
Now: $0.10
Volume52,987 shs
Average Volume72,048 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company is based in Vero Beach, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars

Industry, Sector and Symbol

Industry Agricultural Commodities/Milling
SectorProcess Industries
Current SymbolOTCMKTS:NBIO
Phone(612) 961-5656



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive NBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIO and its competitors with MarketBeat's FREE daily newsletter.

Nascent Biotech (OTCMKTS:NBIO) Frequently Asked Questions

How has Nascent Biotech's stock been impacted by COVID-19 (Coronavirus)?

Nascent Biotech's stock was trading at $0.1450 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBIO shares have decreased by 31.0% and is now trading at $0.10. View which stocks have been most impacted by Coronavirus.

Has Nascent Biotech been receiving favorable news coverage?

Press coverage about NBIO stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Nascent Biotech earned a daily sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutNascent Biotech.

Who are some of Nascent Biotech's key competitors?

What other stocks do shareholders of Nascent Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nascent Biotech investors own include Onconova Therapeutics (ONTX), Ibio (IBIO), CytoDyn (CYDY) and Aytu Bioscience (AYTU).

Who are Nascent Biotech's key executives?

Nascent Biotech's management team includes the following people:
  • Mr. Sean Carrick, Pres, Sec. & Director (Age 51)
  • Mr. Lowell Holden, CFO, Chief Accounting Officer & Director (Age 76)
  • Dr. Brandon J. Price, Exec. VP of Bus. Devel. & Director (Age 71)
  • Mr. Onur Boyman, Co-Founder and Director
  • Mr. Jonathan Sprent, Co-Founder and Director

What is Nascent Biotech's stock symbol?

Nascent Biotech trades on the OTCMKTS under the ticker symbol "NBIO."

How do I buy shares of Nascent Biotech?

Shares of NBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nascent Biotech's stock price today?

One share of NBIO stock can currently be purchased for approximately $0.10.

What is Nascent Biotech's official website?

The official website for Nascent Biotech is www.nascentbiotech.com.

How can I contact Nascent Biotech?

Nascent Biotech's mailing address is 601 21st St Ste 300, VERO BEACH, FL 32960-0860, United States. The company can be reached via phone at (612) 961-5656.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.